Clinical trials: Malignant Melanoma
Melanoma
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma.
- Trial name
- PORTSIDE (NCT05926960)
- Testing
- encorafenib, binimetinib, pembrolizumab
- Where
- 24 sites in Germany, Italy and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Melanoma (Skin Cancer)
A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
This study, called NeoSenti, is exploring whether giving one dose of the immunotherapy drug pembrolizumab before surgery can help the immune system fight melanoma more effectively.
- Trial name
- NeoSenti (NCT07448831)
- Testing
- Pembrolizumab
- Where
- Belgium
- Volunteers
- 49 people
- Sponsor
- Universitair Ziekenhuis Brussel
Familial Pancreatic Cancer
Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma
RATIONALE: Collecting and storing samples of blood and tissue from family members of patients with cancer to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00835133
- Testing
- biologic sample preservation procedure, medical chart review, survey administration
- Where
- United States
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Malignant Melanoma, Drug-Induced Retinopathy
Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant Melanoma
Patients with malignant melanoma are increasingly treated with combined BRAF and MEK inhibitor therapy. Although this treatment has significantly improved survival outcomes, it has been associated with specific retinal changes…
- Trial name
- NCT07427953
- Where
- Slovenia
- Volunteers
- 14 people
- Sponsor
- Institute of Oncology Ljubljana
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Advanced Solid Tumor, RAF Mutation
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation
- Trial name
- NCT06287463
- Testing
- DCC-3084
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Lung Cancer (NSCLC), Lung Cancer (SCLC)
PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor
The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to…
- Conditions
- Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma (Skin Cancer), Melanoma Metastatic
- Trial name
- NCT07442292
- Volunteers
- 40 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma, Skin Cancer
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
The main purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of XL888 when administered orally with vemurafenib plus cobimetinib in participants with BRAF V600 mutated…
- Trial name
- NCT02721459
- Testing
- XL888, Vemurafenib, Cobimetinib
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin), Non Small Cell Lung Cancer
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human…
- Conditions
- Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT06956690
- Testing
- ENV-501
- Where
- 7 sites in United States, Australia
- Volunteers
- 180 people
- Sponsor
- Hummingbird Bioscience
Metastatic Melanoma, Malignant Melanoma
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma
This study evaluates whether interferon-gamma (IFN-γ) expression in tumor tissue and peripheral blood can serve as a predictive biomarker of response to immune checkpoint inhibitors in the first-line treatment of metastatic…
- Conditions
- Metastatic Melanoma, Malignant Melanoma, Skin Cancer
- Trial name
- MAK (NCT07436390)
- Testing
- Pembrolizumab, Nivolumab, Ipilimumab/Nivolumab
- Where
- Slovenia
- Volunteers
- 132 people
- Sponsor
- Institute of Oncology Ljubljana
Melanoma
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or…
- Trial name
- COLUMBUS (NCT01909453)
- Testing
- LGX818, MEK162, vemurafenib
- Where
- 282 sites in United States, Argentina and 27 more
- Volunteers
- 921 people
- Sponsor
- Pfizer
Skin Lesion, Skin Cancer
Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry
This protocol will take measurements of a variety of tumors involving the skin in order to assess changes in tumor oxygen from hyperoxygenation therapy and standard cancer-directed treatments, to demonstrate the clinical…
- Conditions
- Skin Lesion, Skin Cancer, Skin Melanoma, Tumor Skin
- Trial name
- NCT03716193
- Testing
- Oxygen
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- West Virginia University
Cancer
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended…
- Trial name
- NCT04336241
- Testing
- RP2, nivolumab
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Replimune, Inc.
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Low-Dose Liver Radiation (LD-LRT), Non Small Cell Lung Cancer
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver…
- Conditions
- Low-Dose Liver Radiation (LD-LRT), Non Small Cell Lung Cancer, Melanoma, Liver Metastases
- Trial name
- PRIME-LRT (NCT07225036)
- Testing
- LD-LRT
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Jordan Kharofa
Metastatic Malignant Melanoma
Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma
The aim of this prospective clinical study is to evaluate the prognostic and predictive significance of the gastrointestinal microbiome in patients with metastatic malignant melanoma treated with first-line immunotherapy using…
- Trial name
- NCT07428252
- Testing
- PD-1 inhibitors, PD-1 and CTLA-4 inhibitors
- Where
- Slovenia
- Volunteers
- 150 people
- Sponsor
- Institute of Oncology Ljubljana
Melanoma, Non-Melanoma Skin Cancer
Lavender Aromatherapy for Preoperative Anxiety in Melanoma and Epithelioma Patients
This double-blind, randomized, placebo-controlled trial evaluates whether a single 15-minute session of inhalational lavender aromatherapy, administered preoperatively, reduces anxiety in adult patients (ASA I-II) scheduled for…
- Conditions
- Melanoma, Non-Melanoma Skin Cancer, Preoperative Anxiety, pT1a
- Trial name
- LAPAM (NCT07434323)
- Testing
- Lavender Essential Oil
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- San Gallicano Dermatological Institute IRCCS
Cancer, Melanoma
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
- Trial name
- NCT03400332
- Testing
- BMS-986253, Nivolumab, Ipilimumab
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 281 people
- Sponsor
- Bristol-Myers Squibb
Lymphedema, Breast Cancer
Preventing Lymphedema in Axillary Lymph Node Dissection
The researchers are trying to answer if axillary reverse mapping (ARM) with lympho-venous bypass (LVB) in patients undergoing an axillary lymph node dissection reduces the rate and severity of post-operative lymphedema of the arm.
- Conditions
- Lymphedema, Breast Cancer, Melanoma
- Trial name
- NCT03428581
- Testing
- ALND with ARM +/- LVB, ALND
- Where
- 2 sites in United States
- Volunteers
- 264 people
- Sponsor
- Mayo Clinic
Skin Lesions, Melanocytic Nevi
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions.
- Conditions
- Skin Lesions, Melanocytic Nevi, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
- Trial name
- LegitHealth PH (NCT07428941)
- Testing
- AI-based medical device for aided diagnosis in dermatological conditions
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- AI Labs Group S.L